PRME - NASDAQ

Prime Medicine, Inc.

PRME·NASDAQ

$3.21

-2.2%

HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$579.78M

EPS-1.3500

P/E Ratio-2.57

Earnings Date08/06/2026

prme

Total Non-Current Liabilities

Last Annual Value

184.42M

3-Year CAGR

120%

5-Year CAGR

151%

10-Year CAGR

Adjust for Inflation

Prime Medicine, Inc. Competitors Analysis of Total Non-Current Liabilities

PRME · NASDAQ

Company	Total Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Prime Medicine, Inc. NASDAQ:PRME	184.42M	248.5%	111.9%	N/A
ProKidney Corp. NASDAQ:PROK	4.04M	-1.1%	30.5%	N/A
Kura Oncology, Inc. NASDAQ:KURA	447.25M	201.0%	145.8%	50.5%
Septerna, Inc. NASDAQ:SEPN	127.33M	-7.8%	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	20.86M	-6.6%	-17.7%	14.0%
Replimune Group, Inc. NASDAQ:REPL	73.12M	8.4%	19.6%	N/A
Rezolute, Inc. NASDAQ:RZLT	1.45M	-14.8%	-36.9%	13.8%
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	352.95M	-16.7%	-22.7%	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	5.34M	-5.2%	31.7%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	144.73M	-1.9%	-4.4%	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	593.00K	15.1%	N/A	N/A

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.21, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.21

Related Guides

Blog Categories

Continue your PRME research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.